Patents
Literature
3 results about "Antibody receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Family of cell surface molecules which mediate the specific intracellular effects of antibody binding, usually by the Fc region; do not confuse with other antibody-binding moieties which are normally antigens that bind to the Fab region.
Caspr2 chimeric autoantibody receptor
PCT designated stageWO2026125719A1Immunoglobulin superfamilyAnimals/human peptidesAutoantibodyCONTACTIN-ASSOCIATED PROTEIN
The invention relates to a chimeric autoantibody receptor (CAAR) comprising an autoantigen of a Contactin-associated protein-like 2 (CASPR2) protein or one or more autoantigenic fragments thereof. The invention relates further to a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid comprising a sequence encoding an autoantigen, wherein said autoantigen comprises or consists of Contactin-associated protein-like 2 (CASPR2) or one or more fragments thereof, a sequence encoding a transmembrane domain, and a sequence encoding an intracellular signaling domain. The invention further relates to a nucleic acid vector comprising a nucleic acid molecule encoding the chimeric autoantibody receptor (CAAR) of the invention. The invention relates further to a genetically modified cell comprising a nucleic acid molecule or a vector of the invention and / or expressing a CAAR according to the invention.
Owner:DEUT ZENT FUER NEURODEGENERATIVE ERKRANKUNGEN EV +1
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
ActiveUS12637501B2Polypeptide with localisation/targeting motifImmunoglobulin superfamilyMedicineAntibody receptor
The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Chimeric autoantibody receptors (CAARS) targeting EBNA-1 molecular mimics - glialcam, and linked biomarkers
The present disclosure relates to chimeric autoantibody receptors (CAARs) specific for an autoantibody that targets Epstein-Barr Virus nuclear antigen 1 (EBNA1) molecular mimics - GlialCAM, aB Crystallin (CRYAB), and Anoctamin-2 (ANO-2), vectors comprising the CAARs, and genetically modified cells comprising the CAARs. Pharmaceutical compositions and kits comprising the same are provided, as well as methods of diagnosing and methods of treating, preventing, and / or managing multiple sclerosis are provided.
Owner:STEINMAN LAWRENCE